Updated on 2025/04/04

写真a

 
Watanabe Kenta
 
Organization
Scheduled update Assistant Professor
Position
Assistant Professor
External link

Degree

  • Doctor of Medicine ( 2000.3   Okayama University )

Research Interests

  • 放射線治療

Research Areas

  • Life Science / Radiological sciences  / radiotherapy

Research History

  • Okayama University   Radiology   Assistant Professor

    2024.4

      More details

    Country:Japan

    researchmap

  • Kawasaki Medical School   放射線腫瘍学   Lecturer

    2021.4 - 2024.3

      More details

    Country:Japan

    researchmap

  • 岡山大学病院   医員

    2016.4 - 2021.3

      More details

    Country:Japan

    researchmap

 

Papers

  • Long-term outcomes of salvage high-dose-rate brachytherapy for localized recurrence of prostate cancer following definitive radiation therapy: a retrospective analysis Reviewed

    Kenta Watanabe, Nobuhiko Kamitani, Naoki Ikeda, Yujiro Kawata, Ryoji Tokiya, Takafumi Hayashi, Yoshiyuki Miyaji, Tsutomu Tamada, Kuniaki Katsui

    BMC Cancer   25 ( 1 )   2025.3

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1186/s12885-025-13918-2

    researchmap

    Other Link: https://link.springer.com/article/10.1186/s12885-025-13918-2/fulltext.html

  • Radiation‑induced pleomorphic liposarcoma after hypofractionated radiotherapy following breast‑conserving surgery: A case report and literature review. Reviewed International journal

    Kenta Watanabe, Ryoji Tokiya, Yujiro Kawata, Takeshi Matsuno, Ryo Tanaka, Naruto Taira, Kuniaki Katsui

    Oncology letters   28 ( 1 )   325 - 325   2024.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    Breast cancer is one of the leading causes of cancer globally. Radiotherapy following breast-conserving surgery is the standard treatment of breast cancer. Recently, hypofractionated irradiation comprising 42.56 Gy in 16 fractions was selected as a viable radiation therapeutic option. Radiation-induced sarcoma is the most prevalent secondary malignancy in patients undergoing radiotherapy after breast cancer surgery. Angiosarcomas are the predominant type of radiation-induced sarcomas, whereas liposarcomas have rarely been reported. The present report details an uncommon instance of radiation-induced pleomorphic liposarcoma that occurred 8 years after breast-conserving surgery and hypofractionated radiotherapy. The patient visited the hospital due to hardening of the tissue beneath the skin of the right breast. Ultrasonography revealed a hypoechoic mass in the lower part of the right breast containing internal blood flow. An excisional biopsy revealed that the tumor contained infiltrating spindle-shaped cells without a capsule containing pleomorphic cells. Lipoblasts were also observed and tended to differentiate into adipose tissue, leading to a diagnosis of pleomorphic liposarcoma. Immunostaining revealed negativity for cytokeratin AE1/AE3, ERG, MDM2 and S-100 protein; the Ki-67 index was ~20%. An enlargement resection involving a postoperative bed was performed because of close tumor margins. 18F-fluorodeoxyglucose positron emission tomography/computed tomography revealed pale accumulation of 18F-fluorodeoxyglucose in the right chest wall, which was interpreted as a postoperative change owing to the resection biopsy. The tumor was observed in the irradiated field with no distant metastases. Following extensive resection, the patient maintained a recurrence-free survival period of 3 years and 2 months, during which no adjuvant therapy was administered. Therefore, follow-up is necessary in patients with breast cancer treated with radiotherapy.

    DOI: 10.3892/ol.2024.14457

    PubMed

    researchmap

  • Long-term outcomes of high-dose-rate brachytherapy and external beam radiotherapy without hormone therapy for high-risk localized prostate cancer. Reviewed

    Nobuhiko Kamitani, Kenta Watanabe, Naoki Ikeda, Yujiro Kawata, Ryoji Tokiya, Takafumi Hayashi, Yoshiyuki Miyaji, Tsutomu Tamada, Kuniaki Katsui

    Japanese journal of radiology   42 ( 11 )   1322 - 1329   2024.6

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Until March 2018, patients with high-risk localized prostate cancer had been administered high-dose-rate brachytherapy (HDR-BT) combined with external beam radiotherapy (EBRT) without additional hormone therapy (HT) at our institution. In this study, we aimed to evaluate long-term outcomes of this treatment. MATERIALS AND METHODS: Patients with prostate cancer who received HDR-BT and EBRT between April 1997 and March 2021 and who were followed up for at least 6 months were included in the study. High-risk groups were classified into five levels according to the National Comprehensive Cancer Network guidelines. The EBRT and HDR-BT doses were 39-45 Gy/13-25 fractions. and 16.5-22 Gy/2-4 fractions, respectively. None of the patients received HT during initial treatment. The Kaplan-Meier method was used to estimate biochemical freedom from failure (bFFF), cause-specific survival (CSS), and overall survival (OS) rates. Biochemical failure was also determined. RESULTS: Seventy-two patients were enrolled in the study, with a median follow-up of 91.9 months. The median age and initial prostate-specific antigen (iPSA) level were 71 years and 10.95 ng/mL, respectively. The median biologically effective dose for HDR-BT plus EBRT was 270.3 Gy. The 5- and 7-year bFFF, CSS, and OS rates were 85.2 and 74.2%, 100 and 100%, and 95.7 and 91.9%, respectively. Only the iPSA ≤ 20 group was associated with the higher bFFF rate. The 7-year bFFF rates in the groups with iPSA ≤ 20 and iPSA > 20 were 86.6 and 48.6%, respectively. CONCLUSION: HDR-BT plus EBRT without HT might be an alternative treatment option for patients with high-risk localized prostate cancer and iPSA levels ≤ 20. Further studies are required to validate the efficacy of this treatment strategy.

    DOI: 10.1007/s11604-024-01621-4

    PubMed

    researchmap

  • Rectal ulcer associated with lenvatinib 15 years after definitive radiotherapy for prostate cancer: A case report. Reviewed International journal

    Yujiro Kawata, Kenta Watanabe, Ryoji Tokiya, Yoshiyuki Miyaji, Akiko Shiotani, Kuniaki Katsui

    Oncology letters   27 ( 1 )   6 - 6   2024.1

     More details

    Authorship:Corresponding author   Language:English   Publishing type:Research paper (scientific journal)  

    Lenvatinib is a multi-kinase inhibitor that blocks vascular endothelial growth factor, fibroblast growth factor and platelet-derived growth factor receptors. The present study describes a case of rectal ulceration triggered by lenvatinib treatment for hepatocellular carcinoma 15 years after definitive radiotherapy for prostate cancer. A 58-year-old man underwent definitive external beam radiotherapy and high-dose-rate brachytherapy for prostate cancer. A total of 15 years after radiotherapy for prostate cancer, the patient was diagnosed with hepatocellular carcinoma with multiple metastases. Treatment with 12 mg/day lenvatinib was commenced. A total of 4 months after starting lenvatinib therapy, the patient experienced persistent anal pain with a deep ulceration of the anterior wall of the lower rectum. As the pain did not improve, the patient chose to undergo a colostomy, resulting in the resolution of the anorectal pain. To the best of our knowledge, the present case report is the first to report on lenvatinib-induced rectal ulcers after radiotherapy.

    DOI: 10.3892/ol.2023.14139

    PubMed

    researchmap

  • Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis. Reviewed International journal

    Kenta Watanabe, Nobuhiko Kamitani, Naoki Ikeda, Yujiro Kawata, Ryoji Tokiya, Takafumi Hayashi, Yoshiyuki Miyaji, Tsutomu Tamada, Kuniaki Katsui

    Brachytherapy   23 ( 2 )   179 - 187   2024

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: High-dose-rate brachytherapy (HDR-BT) delivers high-dose radiation to local lesions within a short treatment period. There are no reports of salvage transurethral HDR-BT for biochemical recurrence (BCR) after radical prostatectomy. Thus, we aimed to evaluate the usefulness of salvage transurethral HDR-BT with external beam radiation therapy (EBRT) for anastomotic prostate cancer recurrence. METHODS AND MATERIALS: Patients with postoperative prostate cancer who underwent salvage transurethral HDR-BT with EBRT for anastomotic recurrence at our hospital between January 2002 and July 2009 were retrospectively evaluated. The Kaplan-Meier method was used to estimate biochemical freedom from failure (bFFF), cause-specific survival (CSS), and overall survival (OS) rates. RESULTS: Nine patients were included in this study. The median follow-up period and age were 13.1 (range 4.3-18.4) years and 67 (range 63-78) years, respectively. The dose of HDR-BT ranged from 13 to 24 Gy per 2 to 5 fractions, while that of EBRT ranged from 30 to 44 Gy per 15 to 22 fractions. The 1-year, 5-year, and 10-year bFFF rates were 77.8%, 41.7%, and 13.9%, respectively. The 10-year and 15-year CSS rates were 100% each. The 10-year and 15-year OS rates were 100% and 64.3%, respectively. Six patients were diagnosed with BCR. Two patients experienced Grade 3 hematuria as a late adverse event. There was no exacerbation of urinary incontinence. CONCLUSIONS: No prostate cancer-related deaths were observed, even after a long-term follow-up. Salvage transurethral HDR-BT after radical prostatectomy is safe and feasible and may be a useful treatment option.

    DOI: 10.1016/j.brachy.2023.12.004

    PubMed

    researchmap

  • Radiotherapy for ductal carcinoma of the prostate: an analysis based on the Japanese radiation oncology study group survey. Reviewed International journal

    Hidemasa Kawamura, Katsumasa Nakamura, Yasuo Yoshioka, Satoshi Itasaka, Natsuo Tomita, Masahiro Onishi, Hiromitsu Iwata, Takuya Aizawa, Koyo Kikuchi, Kenji Nagata, Kiyonao Nakamura, Kentaro Nishioka, Hiromichi Ishiyama, Shuichi Ueno, Masaki Kokubo, Hideya Yamazaki, Kenta Watanabe, Tatsuya Toyoda, Tetsuo Akimoto

    Japanese journal of clinical oncology   53 ( 2 )   146 - 152   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The clinical characteristics of prostate ductal carcinoma is still unclear, and treatment strategy has not yet been established due to its rarity. Therefore, we conducted a multicenter survey of radiation therapy for prostate ductal carcinoma in Japan. METHOD: Data of patients with ductal carcinoma of the prostate treated with radiation therapy between 1996 and 2018 were extracted from the database of each facility. RESULTS: Fifty-two treatment records of 41 patients were collected from nine institutions. The treatment purpose and situations were varied curative intent to palliation. Twenty-eight patients received curative treatments. The median follow-up period of these patients was 68 months. Androgen deprivation therapy was combined with radiation therapy in 26 cases (93%). X-ray and particle irradiation was used. Radiation dose range was 63-78 Gy; 5-year overall survival, progression-free survival and biochemical relapse-free survival were 87.0, 79.3 and 79.3%, respectively. One patient experienced Grade 3 radiation proctitis and one experienced Grade 3 radiation cystitis. There were no Grade 4 or worse adverse events. CONCLUSION: Most patient received similar treatment with adenocarcinoma of prostate, and the clinical results were compatible. For more reliable evidence, further studies are required.

    DOI: 10.1093/jjco/hyac180

    PubMed

    researchmap

  • 放射線治療を行った進行副乳癌3例の検討. Reviewed

    池田尚生, 釋舍竜司, 河田裕二郎, 渡邉謙太, 西村広健, 田中 了, 平 成人, 勝井邦彰

    臨床放射線   68 ( 11 )   1127 - 1132   2023

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    researchmap

  • Feasibility of magnetic resonance imaging-ultrasound guided high-dose-rate brachytherapy for localized prostate cancer: Preliminary results from a prospective study. Reviewed International journal

    Nobuhiko Kamitani, Yoshiyuki Miyaji, Tsutomu Tamada, Eisaku Yoden, Yujiro Kawata, Kenta Watanabe, Ryouji Tokiya, Atsushi Nagai, Kuniaki Katsui

    International journal of urology : official journal of the Japanese Urological Association   29 ( 7 )   725 - 732   2022.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: This study aimed to investigate preliminary outcomes of a prospective trial of magnetic resonance imaging-ultrasound fusion-guided ultrafocal high-dose-rate brachytherapy in localized prostate cancer. METHODS: In our prospective study, data from patients who underwent this treatment between April 1, 2020 and March 31, 2021 were analyzed. In the procedure, the applicator needle was inserted through the perineum to target the lesion on the multiparametric magnetic resonance imaging, which was fused onto the transrectal ultrasound image. The prescription dose was set at a single fraction of 19 Gy. Data from patients who received whole-gland high-dose-rate brachytherapy were extracted and compared with data from patients who received ultrafocal high-dose-rate brachytherapy, to evaluate the frequency of acute adverse events. RESULTS: Eight patients underwent ultrafocal high-dose-rate brachytherapy with a median observation period of 7.75 months (range 5.96-15.36 months). No acute genitourinary or gastrointestinal adverse events were observed in this cohort. The planned procedure was completed in all patients, and no unexpected adverse events were observed; however, prostate-specific antigen failure was detected in one patient. In the 25 patients who underwent whole-gland high-dose-rate brachytherapy, acute genitourinary and gastrointestinal adverse events were observed in 88% and 20% of the patients, respectively. Ultrafocal high-dose-rate brachytherapy was a significant factor in avoiding acute adverse genitourinary events in univariate and multivariate analyses (P < 0.001 and P = 0.032, respectively). CONCLUSIONS: Magnetic resonance imaging-ultrasound fusion-guided ultrafocal high-dose-rate brachytherapy in localized prostate cancer is a safe and feasible treatment without acute genitourinary and gastrointestinal adverse events. Long-term observation and further investigation are warranted.

    DOI: 10.1111/iju.14880

    PubMed

    researchmap

  • New field-in-field with two reference points method for whole breast radiotherapy: Dosimetric analysis and radiation-induced skin toxicities assessment. Reviewed International journal

    Nouha Tekiki, Masahiro Kuroda, Hinata Ishizaka, Abdullah Khasawneh, Majd Barham, Kentaro Hamada, Kohei Konishi, Kohei Sugimoto, Kuniaki Katsui, Soichi Sugiyama, Kenta Watanabe, Kotaro Yoshio, Norihisa Katayama, Takeshi Ogata, Hiroki Ihara, Susumu Kanazawa, Junichi Asaumi

    Molecular and clinical oncology   15 ( 3 )   193 - 193   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The usefulness of the field-in-field with two reference points (FIF w/ 2RP) method, in which the dose reference points are set simultaneously at two positions in the irradiation field and the high-dose range is completely eliminated, was examined in the present study with the aim of decreasing acute skin toxicity in adjuvant breast radiotherapy (RT). A total of 573 patients with breast cancer who underwent postoperative whole breast RT were classified into 178 cases with wedge (W) method, 142 cases with field-in-field without 2 reference points (FIF w/o 2RP) method and 253 cases with FIF w/ 2RP method. Using the FIF w/ 2RP method, the high-dose range was the lowest among the three irradiation methods. The planning target volume (PTV) V105% and the breast PTV for evaluation (BPe) V105% decreased to 0.09 and 0.10%, respectively. The FIF w/ 2RP method vs. the FIF w/o 2RP method had a strong association (η) with PTV V105% (η=0.79; P<0.001) and BPe V105% (η=0.76; P<0.001). The FIF w/ 2RP method had a significant impact on lowering the skin toxicity grade in weeks 3 and 4, and increasing the occurrence of skin toxicity grade 0. The FIF w/ 2RP method vs. the W method had a moderate association with skin toxicity grade at week 3 (η=0.49; P<0.001). Using the FIF w/ 2RP method, the high-dose range V105% of the target decreased to 0%, and skin adverse events were decreased in conjunction. For patients with early-stage breast cancer, particularly patients with relatively small-sized breasts, the FIF w/ 2RP method may be an optimal irradiation method.

    DOI: 10.3892/mco.2021.2355

    PubMed

    researchmap

  • Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer. Reviewed

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Acta medica Okayama   75 ( 3 )   269 - 277   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Palliative concurrent chemoradiotherapy (CCRT) is often administered to patients with stage III non-small cell lung cancer (NSCLC). We investigated the clinical outcomes of patients receiving palliative CCRT for NSCLC. Data of patients with NSCLC who underwent palliative CCRT (n=16), preoperative CCRT plus surgery (n=97), or definitive CCRT (n=48) were evaluated. In all groups, the concurrent chemotherapy regimens consisted of cisplatin and docetaxel. Rates of local control (LC), distant metastasis-free survival (DMFS), progression-free survival (PFS), overall survival (OS), and prognosis were compared. The 2-year rates of LC, DMFS, PFS, and OS in 16 patients who underwent palliative CCRT were 44.4%, 12.5%, 12.5%, and 18.8%, respectively. Univariate analysis showed that palliative CCRT was associated with poor LC (p<0.001), DMFS (p<0.001), PFS (p<0.001), and OS (p<0.001) outcomes in patients who completed CCRT as a preoperative treatment and poor LC (p=0.01), DMFS (p=0.003), PFS (p=0.04), and OS (p=0.004) outcomes in patients who were considered for definitive CCRT. Although there were some long-term survivors, the clinical outcomes of palliative CCRT were significantly inferior to those of the ideal treatments. Therefore, careful determination of the appropriate treatment indications and further studies are warranted.

    DOI: 10.18926/AMO/62218

    PubMed

    researchmap

  • Investigation into the Effect of Breast Volume on Irradiation Dose Distribution in Asian Women with Breast Cancer. Reviewed

    Hinata Ishizaka, Masahiro Kuroda, Nouha Tekiki, Abdullah Khasawneh, Majd Barham, Kentaro Hamada, Kohei Konishi, Kohei Sugimoto, Kuniaki Katsui, Soichi Sugiyama, Kenta Watanabe, Kotaro Yoshio, Norihisa Katayama, Takeshi Ogata, Hiroki Ihara, Masataka Oita, Susumu Kanazawa, Junichi Asaumi

    Acta medica Okayama   75 ( 3 )   307 - 314   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Reports on irradiation dose distribution in breast cancer radiotherapy with sufficient sample size are limited in Asian patients. Elucidating dose distribution in Asian patients is particularly important as their breast volume differs compared to patients in Europe and North America. Here, we examined dose distribution in the irradiation field relative to breast volume for three irradiation methods historically used in our facility. We investigated the influence of breast volume on each irradiation method for Asian women. A total of 573 women with early-stage breast cancer were treated with breast-conserving surgery and adjuvant radiotherapy. Three methods were compared: wedge (W), field-in-field (FIF), and wedge-field-in-field (W-FIF). In patients with small breast volume, FIF decreased low- and high-dose areas within the planning target volume, and increased optimal dose area more than W. In patients with medium and large breast volumes, FIF decreased high-dose area more than W. The absolute values of correlation coefficients of breast volume to low-, optimal-, and high-dose areas and mean dose were significantly lower in FIF than in W. The correlation coefficients of V107% were 0.00 and 0.28 for FIF and W, respectively. FIF is an excellent irradiation method that is less affected by breast volume than W in Asian breast cancer patients.

    DOI: 10.18926/AMO/62225

    PubMed

    researchmap

  • Sarcopenia is related to poor prognosis in patients after trimodality therapy for locally advanced non-small cell lung cancer Reviewed

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Masaomi Yamane, Takao Hiraki, Katsuyuki Kiura, Shinichi Toyooka, Susumu Kanazawa

    International Journal of Clinical Oncology   26 ( 8 )   1450 - 1460   2021.4

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1007/s10147-021-01927-7

    researchmap

    Other Link: https://link.springer.com/article/10.1007/s10147-021-01927-7/fulltext.html

  • Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study. Reviewed International journal

    Kenta Watanabe, Kuniaki Katsui, Soichiro Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Radiation oncology (London, England)   16 ( 1 )   39 - 39   2021.2

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Stereotactic body radiation therapy (SBRT) is an established therapy for medically inoperable early-stage non-small cell lung cancer (NSCLC). Many elderly patients are medically inoperable owing to comorbidities. Therefore, SBRT may be a useful therapy for elderly patients. However, the application of SBRT for patients aged ≥ 80 years has not been completely elucidated. Therefore, this study aimed to assess the clinical utility of SBRT for elderly patients aged ≥ 80 years with pathologically proven early-stage NSCLC. METHODS: We retrospectively evaluated the data of patients aged ≥ 80 years with pathologically proven primary NSCLC who underwent SBRT at our institution between January 2009 and March 2020. Treatment outcomes and toxicities were analyzed. We used the Kaplan-Meier method to estimate survival curves and the log-rank test to compare the survival curves. We performed univariate and multivariate Cox regression analyses. p-values < 0.05 were regarded significant. RESULTS: Sixty-four patients (65 lesions) were included, and the median follow-up period was 38.7 (range 3.5-95.7) months. The median age was 82.9 (range 80.0-94.8) years. Sixteen patients were medically operable, and 48 patients were medically inoperable. The prescribed dose of SBRT was either 48 Gy in four fractions or 60 Gy in 10 fractions. The median survival time was 60.0 months (95% confidence interval, 43.5-71.1). The 1-, 3-, and 5-year local control, cancer-specific survival, progression-free survival, and overall survival rates were 98.4%, 98.4%, 81.0%, and 88.9%; 90.1%, 93.7%, 58.9%, and 68.3%; and 87.4%, 83.5%, 38.2%, and 47.5%, respectively. Multivariate analysis revealed that inoperability and solid nodules were the predictors of poor overall survival after SBRT in elderly patients. Two patients (3.1%) had grade 3 radiation pneumonitis, and one patient (1.6%) had grade 5 radiation pneumonitis. CONCLUSIONS: SBRT was feasible in patients aged ≥ 80 years with NSCLC. It achieved good local control with minimal toxicity. SBRT may be beneficial in elderly patients with early-stage NSCLC.

    DOI: 10.1186/s13014-021-01769-7

    PubMed

    researchmap

  • A PET/CT volumetric parameter predicts prognosis of non‑small cell lung cancer treated using preoperative chemoradiotherapy and surgery: A retrospective case series study Reviewed

    Kuniaki Katsui, Takeshi Ogata, Akihiro Tada, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Katsuyuki Kiura, Takao Hiraki, Shinichi Toyooka, Susumu Kanazawa

    Molecular and Clinical Oncology   14 ( 4 )   2021.2

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Spandidos Publications  

    DOI: 10.3892/mco.2021.2235

    researchmap

  • Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters. Reviewed International journal

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Norihisa Katayama, Masahiro Kuroda, Katsuyuki Kiura, Takao Hiraki, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    Cancer medicine   9 ( 13 )   4540 - 4549   2020.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Radiation pneumonitis (RP) is a major pulmonary adverse event of chest radiotherapy. The PACIFIC trial that identified durvalumab as an effective subsequent-line therapy after concurrent chemoradiotherapy (CCRT) found that patients with grade 2 or higher RP may have to be excluded from treatment under certain criteria. The purpose of this study was to investigate the relationship between grade ≥2 RP and the parameters of dose-volume histograms after CCRT with cisplatin/docetaxel for stage III non-small cell lung cancer and conduct a subset analysis of severe RP that can lead to the permanent discontinuation of treatment per the PACIFIC trial criteria to help determine treatment strategy. METHODS: We calculated the percentage of the lung volume received at least 5 Gy (V5) and 20 Gy (V20), the mean lung dose (MLD), and the lung volume spared from a 5 Gy dose (VS5) to the total lung volume. Factors affecting the incidence of grade ≥2 RP were identified; severe RP was defined as grade ≥3 as well as grade 2 RP that required ≥10 mg prednisolone for at least 12 weeks. RESULTS: This study included 45 patients. On univariate analysis, all parameters and total lung volume were found to be significant predictors of grade ≥2 RP (P = .001, .003, .03, .004, and .02, respectively). On multivariate analysis, V20 was a significant predictive factor of grade ≥2 RP (P = .007). Severe RP developed in 6 of 37 patients (16.2%) whose V20 values were 35% or lower. On univariate analysis, only V20 was a significant predictor of severe RP in these patients (P = .01). CONCLUSIONS: The best approach to reduce the rate of grade ≥2 RP is to maintain the V5, V20, MLD, and VS5 as low as possible during radiotherapy planning in patients receiving definitive CCRT with cisplatin/docetaxel.

    DOI: 10.1002/cam4.3093

    PubMed

    researchmap

  • Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis. Reviewed International journal

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Norihisa Katayama, Junichi Soh, Masahiro Kuroda, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa

    BMC cancer   19 ( 1 )   1144 - 1144   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The relationship between lung dose-volume histogram (DVH) parameters and radiation pneumonitis (RP) associated with induction concurrent chemoradiotherapy (CCRT) followed by surgery in patients with non-small cell lung cancer (NSCLC) is unclear, particularly when concerning irradiation of the whole lung prior to resection. We performed this study to identify factors associated with grade ≥ 2 RP in such patients. METHODS: Patients who received induction CCRT (chemotherapy: cisplatin and docetaxel; radiotherapy: 46 Gy/23 fractions) between May 2003 and May 2017 were reviewed. The mean lung dose (MLD) and the percentage of the lung volume that received ≥5 Gy (V5) and ≥ 20 Gy (V20) were calculated. Factors associated with the development of grade ≥ 2 RP were analyzed. RESULTS: One hundred and eight patients were included in this study, 34 (31.5%) of whom experienced grade ≥ 2 RP. A V20 ≥ 21%, an MLD ≥10 Gy, and a lower lobe tumor location were significant predictors of grade ≥ 2 RP on univariate analysis (p = 0.007, 0.002, and 0.004, respectively). Moreover, an MLD ≥10 Gy and lower lobe location were significant predictors of grade ≥ 2 RP on multivariate analysis (p = 0.026 and 0.0043, respectively). The cumulative incidence rates of grade ≥ 2 RP at 6 months were 15.7 and 45.6% in patients with MLDs < 10 Gy and ≥ 10 Gy, respectively, and were 23.5 and 55.6% in patients with upper/middle lobe- vs. lower lobe-located tumors, respectively. CONCLUSIONS: MLD and lower lobe location were predictors of grade ≥ 2 RP in patients who received induction CCRT. It is necessary to reduce the MLD to the greatest extent possible to prevent the occurrence of this adverse event.

    DOI: 10.1186/s12885-019-6359-9

    PubMed

    researchmap

  • Interobserver variability of 3.0-tesla and 1.5-tesla magnetic resonance imaging/computed tomography fusion image-based post-implant dosimetry of prostate brachytherapy. Reviewed International journal

    Kenta Watanabe, Norihisa Katayama, Kuniaki Katsui, Toshi Matsushita, Atsushi Takamoto, Hiroki Ihara, Yasutomo Nasu, Mitsuhiro Takemoto, Masahiro Kuroda, Susumu Kanazawa

    Journal of radiation research   60 ( 4 )   483 - 489   2019.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    This study aimed to compare the interobserver variabilities in magnetic resonance imaging (MRI)/computed tomography (CT) fusion image-based post-implant dosimetry of permanent prostate brachytherapy (PPB) between 1.5-T and 3.0-T MRI. The study included 60 patients. Of these patients, 30 underwent 1.5-T MRI and CT 30 days after seed implantation (1.5-T group), and 30 underwent 3.0-T MRI and CT 30 days after seed implantation (3.0-T group). All patients received PPB alone. Two radiation oncologists performed MRI/CT fusion image-based post-implant dosimetry, and the interobserver variabilities of dose-volume histogram (DVH) parameters [dose (Gy) received by 90% of the prostate volume (prostate D90)], percentage of the prostate volume receiving at least the full prescribed dose (prostate V100), percentage of the prostate volume receiving at least 150% of the prescribed dose (prostate V150), dose (Gy) received by 5% of the urethral volume (urethral D5) and the urethral volume receiving at least 150% of the prescribed dose (urethral V150)] were retrospectively estimated using the paired Student's t test and Pearson's correlation coefficient. The Pearson's correlation coefficients of all DVH parameters were higher in the 3.0-T group than in the 1.5-T group (1.5-T vs 3.0-T: prostate D90, 0.65 vs 0.93; prostate V100, 0.62 vs 0.82; prostate V150, 0.97 vs 0.98; urethral D5, 0.92 vs 0.93; and urethral V150, 0.88 vs 0.93). In the paired Student's t test, no significant differences were observed in any of the DVH parameters between the two radiation oncologists in the 3.0-T group (0.068 ≤ P ≤ 0.842); however, significant differences were observed in prostate D90 (P = 0.004), prostate V100 (P = 0.011) and prostate V150 (P = 0.002) between the oncologists in the 1.5-T group. The interobserver variability of DVH parameters in the MRI/CT fusion image-based post-implant dosimetry analysis of brachytherapy was lower with 3.0-T MRI than with 1.5-T MRI.

    DOI: 10.1093/jrr/rrz012

    PubMed

    researchmap

▼display all

MISC

  • Radiation therapy for oligometastatic bone disease in breast cancer

    Norihisa Katayama, Kuniaki Katsui, Kenta Watanabe, Ryota Nagao, Kaho Otsuki, Takao Hiraki, Susumu Kanazawa

    TRANSLATIONAL CANCER RESEARCH   9 ( 8 )   5096 - 5101   2020.8

     More details

    Language:English   Publishing type:Book review, literature introduction, etc.   Publisher:AME PUBL CO  

    Breast cancer (BCa) frequently metastasizes to the bone. BCa patients with oligometastatic bone diseases have much more favorable outcomes than those with metastatic bone disease. Radiation therapy (RT), especially stereotactic body radiation therapy (SBRT), is advised for the treatment of patients with oligometastatic bone disease in other primary sites. "This line of treatment provided favorable outcomes in patients and resulted in only mild toxicities. A similar strategy has been suggested for treatment of BCa patients with oligometastatic bone disease. BCa, bone-only, or high radiation dose are reported to have been associated with good outcomes in RT for metastatic disease. Furthermore, based on the guidelines provided by the BCa expert panel of the German Society for Radiation Oncology and members of the Working Party of Gynecologic Oncology Breast Committee and in line of the results obtained in other primary sites, our group supports the use of high-dose RT or SBRT for the treatment of BCa patients with oligometastatic bone disease. Additionally, the use of magnetic resonance imaging (MRI) for proper target volume definition and three-dimensional (3D) treatment planning especially for lesions of the trunk are essential for the treatment planning of RT. Of note, several clinical trials have combined RT with immune checkpoint inhibitors for the treatment of BCa patients with metastatic disease. Based on this, we anticipate that combined RT and ICI may serve as a better treatment modality for BCa patients with oligometastatic bone disease.

    DOI: 10.21037/tcr.2020.01.35

    Web of Science

    researchmap

Presentations

  • 腎癌に対しネスキープ®を留置後に定位放射線治療を行った1例

    渡邉謙太, 吉尾浩太郎, 山本倫太郎, 佐治真美子, 稲田亮, 長田 栞, 木村優太, 田邊 新, 平木隆夫

    第11回泌尿器画像診断・治療技術研究会  2024.8.2 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 乳腺原発MALTリンパ腫に放射線治療を施行した症例について

    稲田 亮、渡邉謙太、佐治真美子、山本倫太郎、長田 栞、木村優太、久保遥祐、田邊 新、藤原英晃、吉尾浩太郎、平木 隆夫

    第140回日本医学放射線学会中国・四国地方会  2024.6.9 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 膵癌術後の単発リンパ節再発に対してスペーサ留置後の根治療法を行った1例

    佐治真美子, 稲田亮, 山本倫太郎, 木村優太, 久保遥祐, 田邊新, 渡邉謙太, 吉尾浩太郎, 近藤喜太, 平木隆夫

    第140回日本医学放射線学会 中国・四国地方会  2024.6.9 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 乳癌に対する寡分割照射後に発症した放射線誘発血管肉腫の一例

    河田裕二郎, 渡邉謙太, 釋舍竜司, 松野岳志, 田中了, 平成人, 勝井邦彰

    第140回日本医学放射線学会 中国・四国地方会  2024.6.9 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 術後照射が行われた副乳癌の2例

    池田尚生, 釋舍竜司, 河田裕二郎, 神谷伸彦, 渡邉謙太, 林 貴史, 西村広健, 田中 了, 平 成人, 勝井邦彰

    第139回日本医学放射線学会中国・四国地方会  2023.12.9 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 乳房温存療法後に放射線誘発脂肪肉腫をきたした1例

    渡邉謙太, 河田裕二郎, 釋舍竜司, 松野岳志, 田中 了, 平 成人, 勝井邦彰

    第139回日本医学放射線学会中国・四国地方会  2023.12.9 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 高リスク前立腺癌に対するホルモン療法を併用しない外照射を併用した高線量率組織内照射の長期成績

    神谷伸彦, 渡邉謙太, 池田尚生, 河田裕二郎, 釋舍竜司, 林 貴史, 宮地禎幸, 玉田 勉, 勝井邦彰

    日本泌尿器腫瘍学会 第9回学術集会  2023.10.21 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • ホルモン療法を併用しない高リスク前立腺癌に対する外照射併用高線量率組織内照射の長期治療成績の検討

    神谷伸彦, 渡邉謙太, 池田尚生, 河田裕二郎, 釋舎竜司, 林 貴史, 宮地禎幸, 玉田 勉, 勝井邦彰

    第138回日本医学放射線学会中国・四国地方会  2023.6.25 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • A prospective study of MRI-ultrasound fusion-guided ultrafocal high-dose-rate brachytherapy (HDR-BT) for primary localized prostate cancer

    2023.4.20 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Long-term clinical outcome after high-dose-rate brachytherapy without hormonal therapy for high-risk prostate cancer

    2023.4.16 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 当院における前立腺癌術後吻合部再発に対する外照射併用尿道腔内照射の成績

    渡邉謙太, 神谷伸彦, 河田裕二郎, 池田尚生, 釋舎竜司, 勝井邦彰

    第137回日本医学放射線学会 中国・四国地方会  2022.12.4 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 未治療限局型前立腺癌に対するMRI-US画像融合 ガイド下focal HDR-BTの前向き試験

    神谷伸彦, 宮地禎幸, 玉田 勉, 池田尚生, 河田裕二郎, 渡邉謙太, 釋舎竜司, 林 貴史, 勝井邦彰

    日本放射線腫瘍学会第35回学術大会  2022.11.12 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 限局性前立腺癌におけるMRI-US fusion guided focal HDR-BTの安全性と初期経過について

    神谷伸彦, 宮地禎幸, 玉田 勉, 河田裕二郎, 池田尚生, 渡邉謙太, 釋舍竜司, 林 貴史, 勝井 邦彰

    日本泌尿器腫瘍学会第8回学術集会  2022.10.22 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 限局型前立腺癌に対する ultrafocal HDR-BT の前向き研究の報告

    神谷伸彦, 河田裕二郎, 渡邉謙太, 釋舎竜司, 林 貴史, 宮地禎幸, 玉田 勉, 勝井邦彰

    第136回日本医学放射線学会 中国・四国地方会  2022.5.21 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 限局性前立腺癌に対するMRI-US fusion-guided ultrafocal HDR-BT の前向き研究

    神谷伸彦, 宮地禎幸, 玉田 勉, 河田裕二郎, 池田尚生, 渡邉謙太, 釋舎竜司, 林 貴史, 勝井邦彰

    小線源治療部会第24回学術大会  2022.5.21 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • A preliminary report of a prospective study of MRI-ultrasound fusion-guided ultrafocal high-dose rate brachytherapy for localized prostate cancer

    Nobuhiko Kamitani, Yoshiyuki Miyaji, Tsutomu Tamada, Eisaku Yoden, Kuniaki Katsui, Yujiro Kawata, Kenta Watanabe, Ryouji Tokiya, Atsushi Nagai

    2022.4.16 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  • 胃MALTリンパ腫に対する放射線治療後の肝・腎への有害事象の検討

    釋舍竜司, 余田栄作, 渡邉謙太, 河田裕二郎, 神谷伸彦, 林 貴史, 勝井 邦彰

    日本放射線腫瘍学会第34回学術大会  2021.11 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 前立腺癌への根治的放射線治療を施行し、15年後のLenvatinib投与で直腸潰瘍を来した1例

    河田裕二郎, 余田栄作, 神谷伸彦, 渡邉謙太, 釋舍竜司, 林 貴史, 勝井邦彰

    日本放射線腫瘍学会第34回学術大会  2021.4.16 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 高齢者の非小細胞肺癌に対する定位放射線治療成績

    渡邉謙太, 勝井邦彰, 松田恵治, 杉山聡一, 吉尾浩太郎, 平木隆夫, 黒田昌宏, 金澤右

    第80回日本放射線学会総会  2021.4.16 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Sarcopenia is associated with poor prognosis after concurrent chemoradiotherapy for patients with stage III non-small cell lung cancer.

    Kuniaki Katsui, Takeshi Ogata, Keiji Matsuda, Soichi Sugiyama, Kenta Watanabe, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Susumu Kanazawa

    2021.4 

     More details

    Language:Japanese  

    researchmap

  • 放射線ヨード内用療法前処置中に低Na血症を来した2例

    渡邉謙太, 勝井邦彰, 杉山聡一, 吉尾浩太郎, 平木隆夫, 黒田昌宏, 金澤右, 河内麻里子, 土井原博義, 豊岡伸一

    日本放射線腫瘍学会第33回学術大会  2020.10.1 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 非小細胞肺癌に対する化学放射線療法後の放射線肺臓炎の検討

    勝井邦彰, 尾形 毅, 杉山聡一, 渡邉謙太, 吉尾浩太郎, 黒田昌宏, 木浦勝行, 平木隆夫, 金澤 右

    日本放射線腫瘍学会第33回学術大会  2020.10.1 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Radiation Pneumonitis after Concurrent Chemoradiotherapy with docetaxel/cisplatin for Non-small Cell Lung Cancer: Dose-volume parameters analysis

    Kuniaki Katsui, Takeshi Ogata, Kenta Watanabe, Norihisa Katayama, Masahiro Kuroda, Takao Hiraki, Susumu Kanazawa

    2020.5 

     More details

    Language:Japanese  

    researchmap

  • 右頸部Desmoid-type fibromatosisに対し放射線治療を施行した1例

    渡邉菜津子, 渡邉謙太, 松崎秀信, 片山敬久, 勝井邦彰, 平木隆夫, 金澤右

    第133回日本医学放射線学会 中国・四国地方会  2019.12.15 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 肺癌術前化学放射線療法後における放射線肺炎の予測因子の検討

    勝井邦彰, 尾形 毅, 渡邉謙太, 片山敬久, 平木隆夫, 金澤 右

    第133回日本医学放射線学会 中国・四国地方会、  2019.12.15 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 化学放射線療法を行った肺動脈内膜肉腫の1例

    左村和磨, 片山敬久, 大野 凌, 北山貴裕, 戸田憲作, 渡邉菜津子, 渡邉謙太, 勝井邦彰, 金澤 右, 田端雅弘, 前田嘉信

    第133回日本医学放射線学会 中国・四国地方会  2019.12.15 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 3.0-T及び1.5-T MRI/CTの融合画像による前立腺癌シード治療後の線量計算における観察者間の変動

    渡邉謙太, 片山敬久, 勝井邦彰, 松下利, 井原弘貴, 武本充広, 高本篤, 那須保友, 黒田昌宏, 金澤右

    日本放射線腫瘍学会第32回学術大会、  2019.11.21 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • 3T及び1.5T MRI/CT の融合画像による前立腺癌シード治療後の線量計算における観察者間の変動

    渡邉謙太, 片山敬久, 金澤 右, 勝井邦彰, 松下 利, 高本 篤, 那須保友, 黒田昌宏, 武本充広, 井原弘貴

    第132回日本医学放射線学会 中国・四国地方会  2019.6.15 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 上咽頭明細胞癌に対し放射線治療を施行した1例

    大野凌, 渡邉謙太, 松崎秀信, 片山敬久, 勝井邦彰, 平木隆夫, 金澤右

    第132回日本医学放射線学会 中国・四国地方会  2019.6.15 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • DVH predicts radiation pneumonitis after concurrent induction chemoradiation for non-small cell lung cancer

    Kuniaki Katsui, Takeshi Ogata, Shin Tanabe, Hiro Okawa, Kenta Watanabe, Hiroki lhara, Kotaro Yoshio, Norihisa Katayama, Masahiro Kuroda, Susumu Kanazawa

    2019.4 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 放射性ヨード内用療法時の前処置中に低 Na 血症を来たした1例

    大川広, 勝井邦彰, 田邊新, 渡邉謙太, 片山敬久, 平木隆夫, 金澤右

    第131回日本医学放射線学会 中国・四国地方会  2018.12.8 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • ハイドロゲルスペーサーを併用した前立腺癌密封小線源永久挿入療法の 1例

    田邊新, 片山敬久, 福間省吾, 三道幹大, 大野凌, 大川広, 渡邉謙太, 金澤右

    第131回日本医学放射線学会 中国・四国地方会  2018.12.8 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 放射線治療後、照射野内に水疱性類天疱瘡の発疹を認めた1例

    渡邉謙太, 片山敬久, 橋本倫子, 田邊新, 大川広, 井原弘貴, 勝井邦彰, 金澤右

    日本放射線腫瘍学会第31回学術大会  2018.10.11 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • 当院における限局型小細胞肺癌に対する化学放射線療法の治療成績

    片山敬久, 大川 広, 田邊 新, 渡邉謙太, 井原弘貴, 勝井邦彰, 武本充広, 黒田昌宏, 田端雅弘, 木浦勝行, 前田嘉信, 金澤 右

    日本放射線腫瘍学会第31回学術大会  2018.10.11 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 子宮頸癌に対するCTを用いた3次元画像誘導腔内照射の早期成績

    井原弘貴, 大川 広, 田邊 新, 渡邊謙太, 片山敬久, 勝井邦彰, 黒田昌宏, 金澤 右

    第130回日本医学放射線学会 中国・四国地方会  2018.6 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 放射線治療後、照射野内に水疱性類天疱瘡の発疹を認めた1例

    渡邉謙太, 片山敬久, 橋本倫子, 田邊新, 大川広, 井原弘貴, 勝井邦彰, 金澤右

    第130回日本医学放射線学会 中国・四国地方会  2018.6 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 子宮頸癌に対するCTを用いた3次元画像誘導腔内照射の早期成績

    井原弘貴, 勝井邦彰, 大川 広, 田邊 新, 渡邊謙太, 片山敬久, 金澤 右, 黒田昌宏

    第77回日本医学放射線学会総会  2018.4 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Outcomes of monotherapeutic permanent brachytherapy for Japanese localized prostate cancer

    Norihisa Katayama, Kenta Watanabe, Atsushi Takamoto, Yuko Oiwa, Hiro Okawa, Hiroki Ihara, Kuniaki Katsui, Mitsuhiro Takemoto, Yasutomo Nasu, Susumu Kanazawa

    ESTRO 37  2018.4 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • 当院における限局性小細胞肺癌に対する化学放射線療法の治療成績

    片山敬久, 大川 広, 田邊 新, 渡邉謙太, 井原弘貴, 勝井邦彰, 武本充広, 木浦勝行, 前田 嘉信, 金澤 右

    第77回日本医学放射線学会総会  2018.4 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 当院における限局型小細胞肺癌に対する放射線治療の治療成績

    片山敬久, 大川広, 田邊新, 渡邉謙太, 井原弘貴, 勝井邦彰, 田端雅弘, 木浦勝行, 前田嘉信, 武本充広, 金澤右

    第129回日本医学放射線学会 中国・四国地方会  2017.12.9 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 外照射が奏効した神経芽腫肝転移の1例

    田邊新, 井原弘貴, 松本晋作, 渡邉謙太, 片山敬久, 勝井邦彰, 黒田昌宏, 金澤右

    第129回日本医学放射線学会 中国・四国地方会  2017.12.9 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 前立腺癌シード治療後再発例における治療前MRI陽性部位の術後線量の検討

    片山敬久, 渡邉謙太, 浅野雄大, 松本晋作, 杉山聡一, 勝井邦彰, 井原弘貴, 大岩裕子, 高本 篤, 那須 保友, 武本充広, 黒田昌宏, 金澤 右

    日本放射線腫瘍学会第30回学術大会  2017.11 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 限局性の頭部血管肉腫17例の治療経験

    杉山聡一, 勝井邦彰, 田邊 新, 松本晋作, 渡邉謙太, 井原弘貴, 片山敬久, 黒田昌宏, 金澤 右

    第128回日本医学放射線学会 中国・四国地方会  2017.6 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Single institutional experience of the treatment of angiosarcoma of the scalp

    Ihara H, Katsui K, Hisazumi K, Sugiyama S, Watanabe K, Waki T, Kaji T, Katayama N, Takemoto M, Yamasaki O, Iwatsuki K, Kanazawa S

    ESTRO 36  2017.5 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • Comparison of MRI/CT fusion and CT for prostate post-implant dosimetry using sector analysis

    Norihisa Katayama, Mitsuhiro Takemoto, Atsushi Takamoto, Souichi Sugiyama, Kento Hisazumi, Kenta Watanabe, Hiroki Ihara, Kuniaki Katsui, Yasutomo Nasu, Susumu Kanazawa

    ESTRO 36  2017.5 

     More details

    Language:English   Presentation type:Poster presentation  

    researchmap

  • Comparison of MRI/CT fusion images with CT using sector analysis for post-prostate transplant dosimetry

    Katayama Norihisa, Takemoto Mitsuhiro, Takamoto Atsushi, Sugiyama Souichi, Hisazumi Kento, Watanabe Kenta, Ihara Hiroki, Katsui Kuniaki, Nasu Yasutomo, Kanazawa Susumu

    2017.4 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 同室CTを用いた子宮頚癌に対するIGBTの初期経験

    久住研人, 片山敬久, 杉山聡一, 馬越紀行, 渡邉謙太, 井原弘貴, 勝井邦彰, 金澤右, 依田尚之, 中村圭一郎, 平松祐司, 吉尾浩太郎

    第127回日本医学放射線学会 中国・四国地方会  2016.12.10 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 胸壁に発生した myoepitheliomaの1例

    渡邉謙太, 児島克英, 浅野雄大, 坪井有加, 多田明博, 田中顕之, 佐藤修平, 金澤右

    第127回日本医学放射線学会 中国・四国地方会  2016.12.10 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 当院における限局性前立腺癌に対する密封小線源永久挿入療法の治療成績

    片山敬久, 杉山聡一, 久住研人, 渡邉謙太, 馬越紀行, 金澤右, 井原弘貴, 勝井邦彰, 高本篤, 那須保友, 武本充広

    第127回日本医学放射線学会 中国・四国地方会  2016.12.10 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • A review of treatment outcomes in localized stage gastric malignant lymphoma

    Hiroki Ihara, Katsui Kuniaki, Hisazumi Kento, Sugiyama Souichi, Watanabe Kenta, Katayama Norihisa, Takemoto Mitsuhiro, Kanazawa Susumu

    2016.11 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 当院における限局性前立腺癌に対する密封小線源永久挿入単独療法の治療成績

    片山敬久, 杉山聡一, 久住研人, 渡邉謙太, 馬越紀行, 井原弘貴, 勝井邦彰, 高本 篤, 那須保友, 武本充広, 金澤 右

    日本放射線腫瘍学会第29回学術大会  2016.11 

     More details

    Language:Japanese  

    researchmap

  • 巨大脾腫に対して放射線治療を行ったCLLの一例

    杉山聡一, 久住研人, 渡邉謙太, 井原弘貴, 片山敬久, 勝井邦彰, 金澤 右, 河原道子, 脇 隆博, 渡邉謙太, 藤島 護

    第126回日本医学放射線学会 中国・四国地方会  2016.6.6 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 腹壁から逆行性にアプローチした小腸静脈瘤の1例

    梶田聡一郎, 藤原寛康, 郷原英夫, 平木隆夫, 生口俊浩, 松井裕輔, 正岡佳久, 浅野雄大, 小牧稔幸, 渡邉謙太, 杉山聡一, 馬越紀行, 横田智紗子, 金澤右

    第126回日本医学放射線学会 中国・四国地方会  2016.6.6 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

▼display all

Awards

  • 第80回日本医学放射線学会総会 Cypos賞 Bronz medal

    2021.4   日本放射線学会  

     More details